The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment
Open accessAbstract
Interleukin-12 (IL-12) is an important immunostimulatory cytokine, yet its clinical application has been limited by the systemic toxicity associated with its administration. In this work, we developed a strategy to selectively deliver IL-12 to the tumor environment using genetically engineered lymphocytes. However, peripheral blood lymphocytes (PBLs) transduced with a γ-retroviral vector, which constitutively expressed IL-12, failed to expand in culture due to apoptosis. To circumvent this problem, a vector was designed where IL-12 expression was directed by a composite promoter-containing binding motifs for nuclear factor of activated T-cells (NFAT.hIL12.PA2). The NFAT-responsive promoter was activated to drive IL-12 expression upon the recognition of tumor-specific antigen mediated by a T cell receptor (TCR) that was engineered into the same lymphocytes. We tested the efficacy of the inducible IL-12 vector in vivo in a murine melanoma model. Adoptive transfer of pmel-1 T cells genetically engineered with NFAT-murineIL12 (NFAT.mIL12.PA2) significantly enhanced regression of large established B16 melanoma. Notably, this targeted and controlled IL-12 treatment was without toxicity. Taken together, our results suggest that using the NFAT.hIL12.PA2 vector might be a promising approach to enhance adoptive cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Self-citationSmith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
Manetti, R., Parronchi, P., Giudizi, M. G., Piccinni, M. P., Maggi, E., Trinchieri, G., & Romagnani, S. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.1199 · Cited by 1,665
Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,639
Self-citationJohnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,418
Self-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Self-citationAntitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth-Dreese, F. A., Dellemijn, T. A., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 925
Self-citationLeonard, J. P., Sherman, M. L., Fisher, G. L., Buchanan, L. J., Larsen, G., Atkins, M. B., Sosman, J. A., Dutcher, J. P., Vogelzang, N. J., & Ryan, J. L. (1997) · PubMed · Cited by 820
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma
Daud, A. I., DeConti, R. C., Andrews, S., Urbas, P., Riker, A. I., Sondak, V. K., Munster, P. N., Sullivan, D. M., Ugen, K. E., Messina, J. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6794 · Cited by 701
Interleukin-12: Biological Properties and Clinical Application
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G., & Anichini, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0776 · Cited by 601
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
Self-citationAtkins, M. B., Robertson, M. J., Gordon, M. S., Lotze, M. T., DeCoste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D. J., Garzone, P. D., et al. (1997) · PubMed · Cited by 583
Gubler, U., Chua, A. O., Schoenhaut, D. S., Dwyer, C. M., McComas, W., Motyka, R., Nabavi, N., Wolitzky, A. G., Quinn, P. M., & Familletti, P. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.10.4143 · Cited by 576
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
Karttunen, J., Sanderson, S., & Shastri, N. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.6020 · Cited by 418
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332
CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
Dudley, M. E., Gross, C. A., Langhan, M. M., Garcia, M. R., Sherry, R. M., Yang, J. C., Phan, G. Q., Kammula, U. S., Hughes, M. S., Citrin, D. E., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1297 · Cited by 315
Self-citationEstaquier, J., Idziorek, T., Zou, W., Emilie, D., Farber, C. M., Bourez, J. M., & Ameisen, J. C. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1759 · Cited by 273
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Self-citationHughes, M. S., Yu, Y. Y. L., Dudley, M. E., Zheng, Z., Robbins, P. F., Li, Y., Wunderlich, J., Hawley, R. G., Moayeri, M., Rosenberg, S. A., et al. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.457 · Cited by 231
Self-citationMorgan, R. A., Dudley, M. E., Yu, Y. Y. L., Zheng, Z., Robbins, P. F., Theoret, M. R., Wunderlich, J. R., Hughes, M. S., Restifo, N. P., & Rosenberg, S. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.6.3287 · Cited by 228
Self-citationEisenring, M., vom Berg, J., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 221
Immunotherapy of cancer by IL-12-based cytokine combinations
Weiss, J. M., Subleski, J. J., Wigginton, J. M., & Wiltrout, R. H. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.11.1705 · Cited by 221
The Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
Defects in the interferon‐γ and interleukin‐12 pathways
Rosenzweig, S. D., & Holland, S. M. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00227.x · Cited by 219
Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.
Mehrotra, P. T., Wu, D., Crim, J. A., Mostowski, H. S., & Siegel, J. P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2444 · Cited by 203
Amount of interleukin 12 available at the tumor site is critical for tumor regression.
Colombo, M. P., Vagliani, M., Spreafico, F., Parenza, M., Chiodoni, C., Melani, C. C., & Stoppacciaro, A. (1996) · PubMed · Cited by 174
Chen, X., Lin, X., Zhao, J., Shi, W., Zhang, H., Wang, Y., Kan, B., Du, L., Wang, B., Wei, Y., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.3 · Cited by 173
Gao, P., Ding, Q., Wu, Z., Jiang, H., & Fang, Z. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.08.031 · Cited by 158
Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity in vivo
Lieschke, G. J., Rao, P. K., Gately, M. K., & Mulligan, R. C. (1997) · Nature Biotechnology · doi:10.1038/nbt0197-35 · Cited by 154
Cavallo, F., Carlo, E. D., Butera, M., Verrua, R., Colombo, M. P., Musiani, P., & Forni, G. (1999) · PubMed · Cited by 137
Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S., Lee, M. H., Park, K., Kım, K., Jeong, H. S., Kim, J., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401300057388 · Cited by 132
Anti‐tumor activity of mesenchymal stem cells producing IL‐12 in a mouse melanoma model
Elzaouk, L., Moelling, K., & Pavlovic, J. (2006) · Experimental Dermatology · doi:10.1111/j.1600-0625.2006.00479.x · Cited by 130
Improving Transcriptional Termination of Self-inactivating Gamma-retroviral and Lentiviral Vectors
Schambach, A., Galla, M., Maetzig, T., Loew, R., & Baum, C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300152 · Cited by 127
Cohen, C. J., Zheng, Z., Bray, R. B., Zhao, Y., Sherman, L. A., Rosenberg, S. A., & Morgan, R. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.5799 · Cited by 125
Self-citationInterleukin‐12 regulates the proliferation of Th1, but not Th2 or Th0, clones
Kennedy, M. K., Picha, K. S., Shanebeck, K. D., Anderson, D. M., & Grabstein, K. H. (1994) · European Journal of Immunology · doi:10.1002/eji.1830241002 · Cited by 117
Intratumoral injection of IL-12 plasmid DNA – results of a phase I/IB clinical trial
Mahvi, D. M., Henry, M. B., Albertini, M. R., Weber, S. M., Meredith, K. L., Schalch, H., Rakhmilevich, A. L., Hank, J. A., & Sondel, P. M. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701064 · Cited by 112
Wargo, J. A., Robbins, P. F., Li, Y., Zhao, Y., El‐Gamil, M., Caragacianu, D. L., Zheng, Z., Hong, J. A., Downey, S. G., Schrump, D. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0562-x · Cited by 88
Self-citationPrieto, P. A., Durflinger, K. H., Wunderlich, J. R., Rosenberg, S. A., & Dudley, M. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d367bd · Cited by 80
Self-citationWagner, H., Bollard, C. M., Vigouroux, S., Huls, M. H., Anderson, R. W., Prentice, H. G., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700664 · Cited by 76
Coughlin, C. M., Wysocka, M., Trinchieri, G., & Lee, W. M. F. (1997) · PubMed · Cited by 69
Hooijberg, E., Bakker, A. Q., Ruizendaal, J. J., & Spits, H. (2000) · Blood · doi:10.1182/blood.v96.2.459 · Cited by 65
Gately, M. K. (1993) · Cancer Investigation · doi:10.3109/07357909309018881 · Cited by 47
Finkelstein, S. E., Heimann, D. M., Klebanoff, C. A., Antony, P. A., Gattinoni, L., Hinrichs, C. S., Hwang, L. N., Palmer, D. C., Spiess, P. J., Surman, D. R., et al. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0304120 · Cited by 46
Self-citationLee, S. W., Park, Y., Yoo, J. K., Choi, S. Y., & Sung, Y. C. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.5.2456 · Cited by 42
Fan, H., Walters, C. S., Dunston, G. M., & Tackey, R. (2002) · Cytokine · doi:10.1006/cyto.2002.1958 · Cited by 20
Cited by
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,227
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
Castro, F., Cardoso, A. P., Gonçalves, R. M., Serre, K., & Oliveira, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00847 · Cited by 1,224
TRUCKs: the fourth generation of CARs
Chmielewski, M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 738
CAR immune cells: design principles, resistance and the next generation
Labanieh, L., & Mackall, C. L. (2023) · Nature · doi:10.1038/s41586-023-05707-3 · Cited by 658
Metadata
- Authors
- Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 19
- Issue
- 4
- Pages
- 751-759
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2017209592
- Cited by
- 293
- References
- 48
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.